Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 927 results
Filters: First Letter Of Title is C  [Clear All Filters]
Found 927 results.

Administration, Oral

Okusanya O, Forrest A, DiFrancesco R, et al. "Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks." Antimicrob. Agents Chemother.. 2007;51(5):1822-6.

Adolescent

Wagner GJ, Goggin K, Remien RH, et al. "A closer look at depression and its relationship to HIV antiretroviral adherence." Ann Behav Med. 2011;42(3):352-60.
Macatangay BJC, Zheng L, Rinaldo CR, et al. "Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181." Clin. Vaccine Immunol.. 2010;17(9):1452-9.
Mugavero MJ, May M, Ribaudo HJ, et al. "Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study." J. Acquir. Immune Defic. Syndr.. 2011;58(3):253-60.
Lalama CM, Jennings C, Johnson VA, et al. "Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity." J. Clin. Microbiol.. 2015;53(8):2659-66.
Riddler SA, Haubrich R, A DiRienzo G, et al. "Class-sparing regimens for initial treatment of HIV-1 infection." N. Engl. J. Med.. 2008;358(20):2095-106.
Mugavero MJ, Pence BW, Whetten K, et al. "Childhood abuse and initial presentation for HIV care: an opportunity for early intervention." AIDS Care. 2007;19(9):1083-7.
Tassiopoulos K, Landay A, Collier AC, et al. "CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies." J. Infect. Dis.. 2012;205(11):1730-8.
Vogler MA, Patterson K, Kamemoto L, et al. "Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188." J. Acquir. Immune Defic. Syndr.. 2010;55(4):473-82.

Adult

Thio CL, Smeaton L, Hollabaugh K, et al. "Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks." AIDS. 2015;29(10):1173-82.
McComsey GA, Daar ES, O'Riordan MA, et al. "Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202." J. Infect. Dis.. 2013;207(4):604-11.
Shivakoti R, Yang W-T, Gupte N, et al. "Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation." Clin. Infect. Dis.. 2015;61(1):102-10.
Vogler MA, Patterson K, Kamemoto L, et al. "Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188." J. Acquir. Immune Defic. Syndr.. 2010;55(4):473-82.
Zhou L, Kitch DW, Evans SR, et al. "Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy." Neurology. 2007;68(24):2113-9.
Vahey MT, Wang Z, Su Z, et al. "CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway." AIDS Res. Hum. Retroviruses. 2008;24(8):1047-66.
Taiwo B, Hunt PW, Gandhi RT, et al. "CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2013;63(1):101-4.
Lederman MM, Smeaton L, Smith KY, et al. "Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138." J. Infect. Dis.. 2006;194(12):1677-85.
Bartlett JA, Chen S-S, Quinn JB. "Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview." HIV Clin Trials. 2007;8(4):221-6.
Morris BL, Scott CA, Wilkin TJ, et al. "Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development." HIV Clin Trials. 2012;13(1):1-10.
Riddler SA, Haubrich R, A DiRienzo G, et al. "Class-sparing regimens for initial treatment of HIV-1 infection." N. Engl. J. Med.. 2008;358(20):2095-106.

Pages